Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer

Table 1 Previous studies involving immunohistochemical detection of estrogen receptor-α in non-small cell lung cancer

Ref.	Antibody clone	Location	Detection rates
Canver et al[2]	NS	Nucleus	97%
Ollayos et al[3]	NS	Nucleus	7%
Su et al[4]	NS	Nucleus	6%
Di Nunno et al[5]	1D5	None	0
Omoto et al[6]	1D5	None	0
Dabbs et al[7]	1D5/6F11	None/nucleus	0/67%
Radzikowska et al[8]	1D5/6F11	Nucleus	3%/3%
Kawai et al[9]	HC-20	Cytoplasm	73%
Schwartz et al[10]	1D5/6F11	None	0/0
Wu et al[11]	NS	Cytoplasm	3%
Schwartz et al[12]	HC-20	Cytoplasm	66%
Márquez-Garbán et al[13]	HC-20	Nucleus/cytoplasm	45%/75%
Skov et al[14]	1D5	Nucleus/cytoplasm	3%/55%
Niikawa et al[15]	6F11	Nucleus	54%
Nose et al[16]	HC-20	Cytoplasm	84%
Raso et al[17]	6F11	Nucleus	36%
	HC-20	Nucleus/cytoplasm	5%/42%
	1D5	Nucleus/cytoplasm	34%/18%
Abe et al[18]	6F11	Nucleus	1%
Gomez-Fernandez et al[19]	1D5/6F11/SP-1	Nucleus	8%/14%/27%
Mauro et al[20]	6F11+HC-20	Nucleus/cytoplasm	38%/71%
Stabile et al[21]	HC-20	Nucleus/cytoplasm	39%/54%
Sun et al[22]	HC-20	Cytoplasm	36%
Rades et al[23]	1D5	NS	19%
Shimizu et al[24]	HC-20	Cytoplasm	47%
Rouquette et al[25]	1D5	Nucleus	9%
	F10	Nucleus	8%

NS: Indicates not specified.

Table 2 Previous studies involving immunohistochemical detection of estrogen receptor-α in non-small cell lung cancer

Ref.	Antibody clone	Location	Detection rates
Omoto et al[6]	NS	Nucleus	67%
Kawai et al[9]	H-150	Nucleus	51%
Schwartz et al[10]	PPG5/10	Nucleus	61%
Wu et al[11]	NS	Nucleus	46%
Márquez-Garbán et al[13]	Polyclonal	Nucleus	52%
		Cytoplasm	69%
Skov et al[14]	PPG5/10	Nucleus	84%
Niikawa et al[15]	MS-ER β13-PX1	Nucleus	90%
Alì et al[26]	PPG5/10	Nucleus	75%
Nose et al[16]	H-150	Nucleus	74%
Raso et al[17]	H-150	Nucleus	56%
		Cytoplasm	98%
	14C8	Nucleus	42%
		Cytoplasm	19%
Abe et al[18]	14C8	Nucleus	71%
Mauro et al[20]	NS	Nucleus	40%
		Cytoplasm	64%
Navaratnam et al[27]	14C8	Nucleus	49%
Rouquette et al[25]	Polyclonal	Nucleus	38%
Karlsson et al[28]	14C8	Nucleus	86%
Liu et al[29]	PPG5/10	Nucleus	45%
		Cytoplasm	59%

NS: Indicates not specified.

Table 3 Previous studies of estrogen receptors as prognostic markers in non-small cell lung cancer

Ref.	ER subtype	Methods	Location	Prognosis
Kawai et al[9]	α	IHC	Cytoplasm	Worse
	β	IHC	Nucleus	Better
Wu et al[11]	β	IHC	Nucleus	Better
Schwartz et al[10]	β	IHC	Nucleus	Better (male)
Skov et al[14]	β	IHC	Nucleus	Better (male)
Nose et al[16]	α	IHC	Cytoplasm	Worse
Abe et al[18]	β	IHC	Nucleus	Better
Mauro et al[20]	β	IHC	Nucleus	Better
Olivo-Marston et al[30]	α	RT-PCR	NS	Worse
Stabile et al[21]	β	IHC	Cytoplasm	Worse
Rouquette et al[25]	α	IHC	Nucleus	Better
Rades et al[23]	α	IHC	NS	Worse
Karlsson et al[28]	β	IHC	Nucleus	Better (ADCA)
Liu et al[29]	β2,5	IHC	Cytoplasm	Better

ER: Estrogen receptors; NS: Indicates not specified; ADCA: Adenocarcinoma; IHC: Immunohistochemistry; RT-PCR: Reverse transcription polymerase chain reaction.